Key facts
- Neuron23’s last known valuation is $271.5M (Jun 2025).
- It has raised $310.0M; the latest was Later Stage VC ($96.5M) in Jun 2025.
- Notable investors include SoftBank Investment Advisers, Kleiner Perkins, Blue Owl Capital, Perceptive Advisors, Chimera Capital — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Neuron23
- ·The full record, as it builds
Funding rounds
No funding rounds for Neuron23 are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Neuron23
Developer of an artificial intelligence-based drug discovery model designed for genetically defined neurological and immunological diseases. The company's platform leverages recent advances in human genetics, combined with its state-of-the-art artificial intelligence (AI)-enabled drug discovery and biomarker platforms, to advance therapeutics for devastating diseases, enabling patients suffering from genetic disorders with customized medicines.
- Sector
- Healthcare
- HQ
- South San Francisco, CA, United States
- Founded
- 2018
- Employees
- 54
- Website
- neuron23.com/
- Ownership
- Privately Held (backing)
Neuron23 doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Neuron23 shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Neuron23 in its N-PORT filings yet. We sweep new filings monthly.